This model will help you compete in The Market for CRISPR/Cas9 Genome Editing Products:
- Estimate market size, share and growth by region, industry segment and product category
- Understand the drivers of brand loyalty and compare brand performance
- Measure customer satisfaction with CRISPR/Cas9 products
- Highlight the strengths and weaknesses of competitors and their customers’ likelihood-to-switch
- Compare to 2015 data to monitor trends and identify changes
The CRISPR/Cas9 Toolbox
Following our earlier publication on the CRISPR/Cas9 system, The Market for CRISPR/Cas9 Genome Editing Products, released in June 2015 on the Interactive Market Intelligence platform, a follow-up questionnaire was sent to The Science Advisory Board to quantify how the emergence of CRISPR/Cas9 technology is impacting the use of traditional tools and techniques. The questionnaire was fielded between July 6-8, 2015. For a complimentary copy of this report click here.
Since BioInformatics LLC last published on the CRISPR/Cas9 genome-editing system, the scientific community has witnessed a torrent of new publications while institutions, both private and public alike, have poured over a billion dollars into R&D for the emerging technique. Their investment was well founded. In 2015, CRISPR/Cas9 was seen as the key to unlocking the elusive genome, a predication that 2016 has begun to see fulfilled. With CRISPR/Cas9, researchers have found at their disposal a novel nuclease directing system where the ease of use, rate of performance, and versatility are unparalleled by alternative techniques. CRISPR/Cas9 has not only revitalized genome engineering, it has revolutionized the field.
Since its advent, the CRISPR/Cas9 system has seen exponential increase in applications, each of which constituted novel market trends. Some recent developments include:
- Introduction of synthetic crRNA and tracrRNA that bypass the endogenous steps needed to create sgRNA, effectively eliminating the need for additional cloning and purification steps.
- Cataloging of sgRNAs into libraries that can be screened for novelties, such as the up-regulation of oncogenes in cancer cells.
- Modified Cas9 endonucleases that nick DNA to create single-stranded breaks rather than full, double-stranded cleavage. This method promotes homology-directed repair (HDR), limits off-target effects, and increases the number of sequences that can be used for site-dependent gene modifications.
- Identification and analysis of protein binding domains to direct drug development.
- Directing of chromosomal recombination for high-fidelity mapping of traits of interest, which have in turn lead to the discovery of novel genes.
- Generation of ribonucleoprotein complexes from Cas9 and gDNA. These non-viral nucleases cleave DNA immediately upon invasion, degrade quickly and skip native, time-consuming Cas9 activation pathways.
- Combination of CRISPR/Cas9 with lambda red for recombineering. This allows for the knockout of disparate gene combinations, such as those pivotal in metabolic pathways.
The sheer volume of applications is staggering and, as with any breakthrough, corporate giants have reoriented their priorities while emerging biotechs have sprung up around the world, all in hopes to claim market share. In this rapidly evolving environment, companies are faced with the challenge of leveraging their current strengths to break into a field that is flush with new competition. In the same way that CRISPR/Cas9 afforded scientists the opportunity to expand their reach, so to does our 2016 Market for CRISPR/Cas9 Report equip suppliers with the tools they need to capitalize on this emergent technology.